The company’s subsidiary donates big to attorneys general groups of both parties.
Compared to the last quarter, spending on cannabis-related issues is down somewhat, though some entities are pushing for coronavirus relief.
Two groups, including the campaign arm of The Heritage Foundation, joined an anti-cannabis veteran to oppose cannabis legislation in Congress.
Companies and organizations spent nearly $11 million on federal lobbying alone, vastly outpacing previous years. But given the coronavirus, 2020 is a mystery.
One of the largest and oldest CBD companies hopes to shape the state’s hemp industry, expected to be among the top in the nation.
Syngenta, which rejected an acquisition by Monsanto in 2015, is the latest major agriculture company monitoring the newly-legal market.
The supermarket giant started carrying CBD products last year. Now, it’s pressing the federal government on the issue.
Seven major schools have been working at the federal level toward access to cannabis for research and access to funding for research.
Some of the associations have pushed for the STATES Act, in addition to freedom to research and access to medical cannabis, Cannabis Wire has learned.
The seven tribes and tribal associations refused to comment on their lobbying activities.
All three multi-state operators that registered to lobby also applied for medical cannabis licenses.
Anheuser-Busch Companies, Inc. and Constellation Brands are lobbying on cannabis federally in the US.
Parallel, formerly Surterra, the state’s second largest cannabis company, led the lobbying pack at nearly $95,000.
The company behind Marlboro acquired a 45 percent stake in the Canadian cannabis company Cronos Group earlier this year.
Prominent multistate operators lobbying at the federal level are mainly interested in the SAFE Banking Act.
The US subsidiary of GW Pharmaceuticals, behind the only FDA-approved cannabis extract-based medicine, is lobbying in all 50 states.